Top Industry Leaders in the Diabetic Retinopathy Market
Regenerxbio Announced positive interim data from the ongoing Phase II ALTITUDE trial for RGX-314, a potential treatment for diabetic retinopathy without center-involved diabetic macular edema (CI-DME).
Eyenuk Received FDA clearance for its EyeArt® AI system with enhanced features, expanding capabilities for autonomous AI detection of various stages of diabetic retinopathy in primary care settings.
Exonate Successfully completed a Phase Ib/IIa trial for EXN407, a topical candidate with the potential to be the first topical treatment for diabetic retinopathy and diabetic macular edema.
Roche Diagnostics Introduced the Elecsys BRAF V600E Mutation Test, aiding in targeted treatment decisions for melanoma patients, who are also at risk for diabetic retinopathy.Medtronic: Continues to develop its portfolio of minimally invasive surgical instruments and energy devices for diabetic retinopathy treatment.
List of Diabetic Retinopathy Key Companies in the Market
- Hoffmann-La Roche AG
- Regeneron Pharmaceuticals Inc.
- Alimera Sciences
- Ampio Pharmaceuticals Inc.
- Aurolab
- Allergan PLC
- Abbott Laboratories